Creative Touch Permanent Makeup and Aesthetics

Palmitoyl Tripeptide-1 is the palmitoyl-conjugated form of GHK – the tripeptide sequence glycyl-L-histidyl-L-lysine – modified with a C16 palmitic acid tail to enable stratum corneum penetration. It shares its three amino acid sequence with GHK-Cu (copper tripeptide-1) but is a structurally and functionally distinct ingredient: where GHK-Cu binds a copper ion that drives its carrier peptide and broad gene-regulatory mechanism, Pal-GHK carries no copper and functions exclusively as a signal peptide, delivering the GHK matrikine sequence to fibroblast surface receptors without the copper-mediated enzymatic and antioxidant effects. The palmitoyl conjugation serves the same penetration purpose as in Pal-KTTKS ( Matrixyl) – converting the hydrophilic GHK sequence into a lipopeptide capable of partitioning into the stratum corneum lipid phase.

In fibroblast models, Pal-GHK increases synthesis of collagen I, III, and IV, fibronectin, and glycosaminoglycans in a dose-dependent manner, with maximal stimulation at 0.5–1.0 μM. The signalling pathway involves TGF-β modulation – specifically, Pal-GHK appears to stimulate collagen fibrillogenesis through TGF-β receptor pathway activation whilst simultaneously suppressing excessive TGF-β1 activity through decorin upregulation, which sequesters free TGF-β1 and limits receptor over-activation. This dual TGF-β relationship – stimulating controlled collagen fibril assembly whilst preventing fibrotic over-response – reflects the same balanced remodelling logic seen in the parent GHK sequence and distinguishes Pal-GHK from purely stimulatory signal peptides. peptidejournal

Palmitoyl Tripeptide-1 is best known as one of the two active components in Matrixyl 3000, where it is paired with Palmitoyl Tetrapeptide-7 (an IL-6-suppressing anti-inflammatory peptide). The combination logic is additive: Pal-GHK provides the collagen synthesis signal; Pal-tetrapeptide-7 reduces the inflammatory MMP-driven degradation that would partially offset it. Its independent clinical evidence base is limited – most published data covers the Matrixyl 3000 combination rather than Pal-GHK in isolation – making it an ingredient best understood in formulation context rather than as a standalone active.

→ See: Matrixyl entity for full Matrixyl 3000 mechanism and clinical evidence.

→ See: GHK-Cu entity for the copper-bound GHK variant with its broader gene-regulatory and carrier peptide mechanisms.